Neovacs Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Hugo Brugiere

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

CEO Compensation Analysis

How has Hugo Brugiere's remuneration changed compared to Neovacs's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-€9m

Sep 30 2023n/an/a

-€7m

Jun 30 2023n/an/a

-€5m

Mar 31 2023n/an/a

-€4m

Dec 31 2022n/an/a

-€4m

Sep 30 2022n/an/a

-€8m

Jun 30 2022n/an/a

-€11m

Mar 31 2022n/an/a

-€12m

Dec 31 2021n/an/a

-€12m

Sep 30 2021n/an/a

-€7m

Jun 30 2021n/an/a

-€3m

Mar 31 2021n/an/a

-€5m

Dec 31 2020€85k€75k

-€6m

Compensation vs Market: Insufficient data to establish whether Hugo's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Insufficient data to compare Hugo's compensation with company performance.


CEO

Hugo Brugiere

no data

Tenure

€85,000

Compensation

Mr. Hugo Brugière, M. Sc., has been Director of Pharnext SA since November 2022 and serves as its Chairman and Chief Executive Officer since December 28, 2022. He has been Chief Executive Officer of Cyberg...